Safety And Effectiveness Of First-line Antihypertensive Drug Classes

Press Release : August 18, 2020
Safety And Effectiveness Of First-line Antihypertensive Drug Classes

For those with extremely high blood pressure, or hypertension, there are many initial medication options — so many that it can be hard to know which one to use. Now, a Yale-coauthored paper in Lancet provides more information about the relative safety and effectiveness of different hypertension drugs in order to inform this critical treatment decision. The study reveals that angiotensin converting enzyme (ACE) inhibitors may not be the best choice for initial treatment.

Unprecedented in scale, the Lancet study pulled together the data of 4.9 million patients from nine institutional databases across four countries. The researchers used that data to compare the safety and effectiveness of the five classes of first-line hypertension drugs, including the popular ACE inhibitors. They were looking at how well each drug prevented the three main health consequences of hypertension — heart attack, heart failure, and stroke — and to what extent each drug caused 46 unwanted side-effects.

“This is a remarkable, massive, multinational study that has provided insights that can inform patient choices about hypertension treatment. What is distinctive is not only the size, but the advanced methods that optimize the trustworthiness of the results” said Dr. Harlan Krumholz, Yale cardiologist and author on the Lancet study.

The big data revealed patterns that would otherwise have taken 22,000 typical observational studies to spot, say the researchers. One key finding was that thiazide or thiazide-like diuretics are better at preventing heart attack, heart failure, and stroke than ACE inhibitors, while also being safer than ACE inhibitors. Taken individually, the differences in safety and effectiveness of the treatments might seem small, say the scientists, but at scale, they become significant. The researchers report that if the 2.4 million people in the study currently using ACE inhibitors had instead been using thiazide or thiazide-like diuretics, more than 3,100 major cardiovascular events could potentially have been avoided.

“Given that these drugs are inexpensive and have a long track-record, the findings should clearly turn us away from the prevalent practice of starting with ACE inhibitors. These findings support people opting for a thiazide diuretic over an ACE inhibitor for the initial treatment of hypertension,” Krumholz concludes.

The paper was co-authored by members of the Observational Health Data Science and Informatics (OHDSI) network, a research and data-sharing collaborative based out of Columbia University, and is part of OHDSI’s ongoing Large-Scale Evidence Generation and Evaluation across a Network of Databases (LEGEND) project, which uses big-data analysis to conduct observational research studies on hundreds of millions of patient records.

Distinctly dedicated to bringing differentiated and high-quality services to our global clients, Huateng Pharma is a highly proved provider of comprehensive pharmaceutical services. As a pharmaceutical intermediates manufacturer, we have very copious experience in regard to intermediates for the synthesis of drug substances. We can provide the synthesis of intermediates for antihypertensive drugs such as Selexipag, Olmesartan, Moxonidine, Valsartan and so on.

 

About us

Company name: Hunan Huateng Pharmaceutical Co. Ltd.

Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China

Zip code: 410205

Telephone: +86 731 89916275

Fax: +86 0731-82251112-818

Website: https://en.huatengsci.com

Email:sales@huatengusa.com

Notes to editors

For more information please contact:
Sonia Li Tel: +86 731 89916275 email: sales@huatengusa.com Visit the newsroom of: sunnyfang1419